ERBB2 and ductal breast carcinoma in situ: Ipsilateral in situ recurrence was reduced by 84% by adjuvant radiotherapy in the HER2-positive DCIS patient group, whereas this reduction amounted only to 42% in the HER2-negative DCIS patients [12, 35].